Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / Mar / Prostate Screening Stats Deliver Stark Warning
Oncology Screening and monitoring Clinical care Liquid biopsy

Prostate Screening Stats Deliver Stark Warning

Men who skip prostate cancer screenings face significantly higher risk of death, according to study findings presented at the 2025 European Association of Urology (EAU) Congress in Madrid.

03/28/2025 News 2 min read

Share

Credit: Adobe Stock (Edited)

Consistently avoiding prostate cancer screening appointments increases the risk of dying from the disease, according to new research presented at the European Association of Urology (EAU) Congress in Madrid. The findings, based on long-term data from the world’s largest prostate cancer screening study, shed new light on the impact of screening behavior on patient outcomes.

The analysis draws on 20 years of follow-up from the European Randomized Study of Screening for Prostate Cancer (ERSPC), which has tracked more than 160,000 men across seven European countries. Among the 72,460 men who were invited to regular prostate-specific antigen (PSA) screening tests, around one in six – over 12,400 men – never attended a single appointment. This group had a 45 percent higher risk of dying from prostate cancer compared with those who participated in screenings.

In contrast, men who attended screening appointments had a 23 percent lower risk of death compared with a control group who were never invited. Men who declined screening, however, faced a 39 percent higher risk of dying than the control group – suggesting that choosing not to participate may carry more risk than not being offered screening at all.

Lead researcher Renée Leenen said the findings identify a new high-risk group. “It may be that men who opted not to attend a screening appointment are care avoiders, meaning they’re less likely to engage in healthy behaviours and preventative care in general,” she said. “This is the opposite behavior of people who are perhaps more health conscious and are more likely to attend a screening appointment.”

Prostate cancer is the most common cancer in men across more than 100 countries. Screening programs using PSA blood tests can lead to earlier diagnosis, less aggressive treatment, and improved survival. However, uptake remains a challenge.

Tobias Nordström of the Karolinska Institute, Sweden, added, “We need to better understand why these men might actively choose not to participate in screening, despite being invited to attend, and how this behavior is linked to worse outcomes when they get a diagnosis.”

The full results of this sub-analysis will be published later this year, as part of ongoing efforts to guide evidence-based, risk-adapted screening programmes across Europe through the EAU-led PRAISE-U initiative.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Flexible Solutions With FlexVUE
Screening and monitoring
Flexible Solutions With FlexVUE

December 29, 2021

1 min read

Quickly customize your immune panels with Ultivue’s new innovation

What’s New in Infectious Disease? (December 2021)
Screening and monitoring
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

A Pig In a Poke
Screening and monitoring
A Pig In a Poke

October 21, 2016

1 min read

When importing livestock for food or breeding, European countries may inadvertently open their borders to superbugs as well

Sneaky Superbugs
Screening and monitoring
Sneaky Superbugs

October 21, 2016

1 min read

Norway’s strict LA-MRSA transmission measures prevent the import of almost all live pigs – but the bacteria have found a new way in

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.